Crenolanib is a potent inhibitor of FLT3 with activity against resistance-conferring point mutants-Reference-Cited by-同舟云学术

Crenolanib is a potent inhibitor of FLT3 with activity against resistance-conferring point mutants

Published:2014-01-02 Issue:1 Volume:123 Page:94-100
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Galanis Allison¹,Ma Hayley¹,Rajkhowa Trivikram¹,Ramachandran Abhijit²,Small Donald¹,Cortes Jorge³,Levis Mark¹

Affiliation:

1. Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD;

2. Arog Pharmaceuticals LLC, Dallas, TX; and

3. MD Anderson Cancer Center, University of Texas, Houston, TX

Abstract

Key Points Crenolanib displays activity against several of the important kinase domain mutations (at position D835) found in FLT3. Patients receiving crenolanib achieve FLT3-inhibitory plasma levels.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/123/1/94/1373911/94.pdf

Reference31 articles.

1. FLT3: ITDoes matter in leukemia.;Levis;Leukemia,2003

2. Prognostic relevance of FLT3-TKD mutations in AML: the combination matters—an analysis of 3082 patients.;Bacher;Blood,2008

3. FLT3 D835/I836 mutations are associated with poor disease-free survival and a distinct gene-expression signature among younger adults with de novo cytogenetically normal acute myeloid leukemia lacking FLT3 internal tandem duplications.;Whitman;Blood,2008

4. FLT3 as a therapeutic target in AML: still challenging after all these years.;Kindler;Blood,2010

5. Antitumor activity of sorafenib in FLT3-driven leukemic cells.;Auclair;Leukemia,2007

Cited by 217 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. FLT3-PROTACs for combating AML resistance: Analytical overview on chimeric agents developed, challenges, and future perspectives;European Journal of Medicinal Chemistry;2024-11

2. Developments of Fms-like Tyrosine Kinase 3 Inhibitors as Anticancer Agents for AML Treatment;Current Medicinal Chemistry;2024-09

3. Common Driver Mutations in AML: Biological Impact, Clinical Considerations, and Treatment Strategies;Cells;2024-08-21

4. Inhibitors of the tyrosine kinases FMS-like tyrosine kinase-3 and WEE1 induce apoptosis and DNA damage synergistically in acute myeloid leukemia cells;Biomedicine & Pharmacotherapy;2024-08

5. Mechanisms of Resistance to Targeted Therapies in AML;Annual Review of Cancer Biology;2024-06-12